| Schedule of Operating Financial Results of Therapeutics Segment |
The following table provides the operating financial results of the therapeutics segment: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Revenues: | | | | | | | | | Product sales, net | $ | 173,912 | | | $ | 102,660 | | | $ | 319,299 | | | $ | 180,995 | | | License fees and collaboration revenue | — | | | — | | | 16,667 | | | — | | | Total revenues | 173,912 | | | 102,660 | | | 335,966 | | | 180,995 | | | | | | | | | | | Operating expenses: | | | | | | | | | Cost of sales | 12,113 | | | 6,237 | | | 21,509 | | | 11,448 | | | Research and development | 31,010 | | | 15,594 | | | 53,361 | | | 30,003 | | | Selling and marketing | 90,002 | | | 65,857 | | | 174,484 | | | 126,143 | | | General and administrative | 60,695 | | | 37,156 | | | 112,642 | | | 61,865 | | | Total operating expenses | 193,820 | | | 124,844 | | | 361,996 | | | 229,459 | | | Loss from operations | (19,908) | | | (22,184) | | | (26,030) | | | (48,464) | | Other reconciling items(1) | 1,357 | | | 1,844 | | | 512 | | | 3,004 | | | Net loss | $ | (18,551) | | | $ | (20,340) | | | $ | (25,518) | | | $ | (45,460) | | | | | | | | | | | Other segment disclosures: | | | | | | | | | Interest income | $ | 3,698 | | | $ | 4,229 | | | $ | 7,420 | | | $ | 7,683 | | | Interest expense | $ | (2,156) | | | $ | (2,240) | | | $ | (4,284) | | | $ | (4,453) | | | Depreciation and amortization expense | $ | (1,000) | | | $ | (453) | | | $ | (1,437) | | | $ | (913) | | | Provision for income taxes | $ | (2,716) | | | $ | — | | | $ | (5,068) | | | $ | — | | (1) Other reconciling items primarily includes interest income, gain on exchange of long-term investments, interest expense, and provision for income taxes. |
|